v3.26.1
SEGMENTED INFORMATION (Disclosure of reportable segments) (Details) - CAD ($)
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disclosure of operating segments [line items]    
External net sales $ 166,048 $ 872,495
Cost of sales 1,838,971 644,610
Gross margin (loss) (1,672,923) 227,885
Depreciation and amortisation 526,405 600,322
Interest Expense 139,657 91,323
Net loss (9,767,958) (10,039,658)
Segment assets 15,086,932 18,396,185
Segment liabilities 5,284,788 3,646,738
Capital expenditures 701,862 184,612
IP Development [Member]    
Disclosure of operating segments [line items]    
External net sales 166,048 79,995
Cost of sales 1,838,971 578,419
Gross margin (loss) (1,672,923) (498,424)
Depreciation and amortisation 526,405 600,322
Interest Expense 139,657 91,323
Net loss (6,742,003) (7,075,798)
Segment assets 6,732,071 10,013,831
Segment liabilities 3,698,876 2,816,136
Capital expenditures 2,020 1,398
Biotech [Member]    
Disclosure of operating segments [line items]    
External net sales 0 792,500
Cost of sales 0 66,191
Gross margin (loss) 0 726,309
Depreciation and amortisation 0 0
Interest Expense 0 0
Net loss (599,857) (262,462)
Segment assets 1,989 828,439
Segment liabilities 344,583 238,003
Capital expenditures 0 0
Albany Project [Member]    
Disclosure of operating segments [line items]    
External net sales 0 0
Cost of sales 0 0
Gross margin (loss) 0 0
Depreciation and amortisation 0 0
Interest Expense 0 0
Net loss (433,253) (18,597)
Segment assets 8,352,872 7,553,915
Segment liabilities 741,576 0
Capital expenditures 699,842 183,214
Unallocated Corporate [Member]    
Disclosure of operating segments [line items]    
External net sales 0 0
Cost of sales 0 0
Gross margin (loss) 0 0
Depreciation and amortisation 0 0
Interest Expense 0 0
Net loss (1,992,845) (2,682,801)
Segment assets 0 0
Segment liabilities 499,753 592,599
Capital expenditures $ 0 $ 0